首页> 外文期刊>Endocrinology, Diabetes & Metabolism >Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
【24h】

Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes

机译:在2型糖尿病患者中使用非LDL-C脂质药物

获取原文
           

摘要

Background A number of non‐low‐density lipoprotein cholesterol lipid abnormalities are associated with type 2 diabetes and insulin resistance, which may lead practitioners to use medications targeting these abnormal lipid fractions despite a lack of evidence or guideline recommendations. Methods and Results Among 382?921 US patients with type 2 diabetes (69% with cardiovascular disease, 76% on a statin), 95?995 (26%) were on some nonstatin lipid‐lowering medication—19?265 (5%) on niacin, 32?919 (9%) on a fibrate and 69?513 (18%) on fish oil. Use of all three medications was stable over time and higher in patients with cardiovascular disease and with higher triglyceride levels, although even among patients with triglyceride levels 2.3?mmol/L, 6% were on a fibrate and 17% were on fish oil. Conclusion As clinical trials demonstrate little to no cardiovascular benefit from taking these medications, greater attention is needed to focus the use of lipid‐lowering medications to those with proven benefit.
机译:背景技术许多非低密度脂蛋白胆固醇脂质异常与2型糖尿病和胰岛素抵抗有关,尽管缺乏证据或准则建议,但仍可使用靶向这些异常脂质分数的药物。 382〜921型糖尿病患者的方法和结果(患有心血管疾病的69%,在汀类药物上76%),95〜995(26%)在一些非顿脂质降低药物-19?265(5%)在烟酸,32°(9%)纤维酸盐和69?513(18%)在鱼油上。所有三种药物的使用随着时间的推移和较高的心血管疾病和甘油三酯水平较高的患者稳定,虽然即使甘油三酯水平<2.3?mmol / L的患者,6%均为纤维素,17%在鱼油上。结论随着临床试验表明没有服用这些药物的心血管效益,需要更加关注,将使用降脂药物与经过验证的益处的人们集中使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号